


Express Mail N .: EV328183412US

Date of Deposit: October 9, 2003

10-14-03  
1647  
Attorney Docket No. 22058-514 NATL (GI 5268A NATL)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Collins et al.

SERIAL NO.: 09/868,123

EXAMINER: Regina M. DeBerry

FILING DATE: April 2, 2002

ART UNIT: 1647

FOR: CYTOKINE RECEPTOR CHAIN

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

TRANSMITTAL LETTER


Transmitted herewith for filing in the present application are the following documents:

1. Response to May 9, 2003 Office Action (1 pg.);
2. Petition for Four Month Extension of Time (1 pg.);
3. Check No. 17364 for \$1,440.00;
5. Return Postcard.

The Commissioner is authorized to credit any overpayment or charge any deficiencies to Deposit Account No. 50-0311, Reference No. 22058-514 NATL. A duplicate copy of this Transmittal Letter is enclosed.

If the enclosed papers are considered incomplete, the Mail Room is respectfully requested to contact the undersigned collect at (617) 542-6000, Boston, Massachusetts.

Respectfully submitted,

  
Ivor R. Elrifi, Reg. No. 39,529  
David E. Johnson, Reg. No. 41,874  
Attorneys for Applicants  
c/o MINTZ LEVIN  
One Financial Center  
Boston, Massachusetts 02111  
Tel.: (617) 542-6000  
Fax: (617) 542-2241  
Customer No. 30623

Dated: October 9, 2003

RECEIVED  
OCT 22 2003  
TECH CENTER 1900/2900

Express Mail No.: EV328183412US

Date of Deposit: Oct ber 9, 2003

Attorney Docket No. 22058-514 NATL (GI 5268A NATL)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Collins et al.

SERIAL NO.: 09/868,123

EXAMINER: Regina M. DeBerry

FILING DATE: April 2, 2002

ART UNIT: 1647

FOR: CYTOKINE RECEPTOR CHAIN

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

RECEIVED  
OCT 22 2003  
TECH CENTER 1647

RESPONSE TO REQUIREMENT FOR RESTRICTION

In response to the May 9, 2003 Office Action applicants elect Group V, which is listed in the Office Action as containing claims 23, 28-31, and 39-37 [sic], drawn, in part, to a method of administering protein and a method of treating an IL-13 condition or inhibiting interaction of IL-13 with an IL-13 bc protein in a mammal comprising administering IL-13bc (antagonist) and a pharmaceutically acceptable carrier. Applicants believe that the Examiner intended Group V to include claims 23, 28-31, and 39-47.

Applicants additionally elect the polynucleotide sequence SEQ ID NO:3 and the polypeptide sequence SEQ ID NO:4.

A petition for extension of time accompanies this response. The Commissioner is authorized any additional fees, or to credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 22058-514NATL.

Respectfully submitted,

Ivor R. Elrifi, Reg. No. 39,529  
David E. Johnson, Reg. No. 41,874  
Attorneys for Applicants  
c/o MINTZ LEVIN  
One Financial Center  
Boston, Massachusetts 02111  
Tel.: (617) 542-6000  
Fax: (617) 542-2241